Sandoz outlined a major expansion plan for its newly formed biosimilars unit, including a $300 million investment in a new manufacturing site in Slovenia. The company also said it intends to grow its biosimilar pipeline in that unit by more than sevenfold, signaling a step-up in production capacity and global supply ambitions. The strategy centers on accelerating manufacturing scale to support future biosimilar launches, a critical operational advantage as payers and healthcare systems continue to shift toward lower-cost biologics after patent expiries. For industry participants, the move underscores how biosimilar players are prioritizing not only clinical and regulatory development, but also manufacturing readiness and regional production footprints as demand ramps and competition intensifies.